CYBERKNIFE® SYSTEM FOR PROSTATE CANCER TREATMENT

Proven, Fast and Convenient

Growing clinical evidence demonstrates that the unmatched precision of the CyberKnife® System delivers a beneficial treatment option for men diagnosed with prostate cancer.

Complete the form to talk to an expert about Cyberknife prostate cancer treatment.

UNMATCHED CAPABILITIES

Sub-millimeter accuracy + real-time motion synchronization

Target the tumor and minimize dose to healthy and sensitive tissues with continuous, sub-millimeter robotic precision and exclusive Synchrony technology real-time correction and adaptation

A UNIQUE TREATMENT OPTION

Safe and efficient hypofractionated SBRT

Safely deliver hypofractionated SBRT treatments with complete confidence, delivering treatment in as little as 5 treatments or fewer — compared to 20-39 treatment with conventional radiotherapy.

POWERFUL OUTCOMES

Maximize patient quality of life

CyberKnife SBRT is delivered in an outpatient procedure – no incisions, no general anesthesia and no hospitalization – enabling patients to get back to everyday life quickly.

Clinical Evidence Continues Growing

Powerful results from two of the largest studies demonstrates excellent control and minimized toxicity with CyberKnife SBRT.

A Safe Alternative to
Conventional Fractionation1

Excellent Cancer Control
Five-year biochemical disease free survival was 97% for the whole group of patients. 

Low Side Effects
Toxicity and side effects were uncommon and similar to other radiation therapy treatments including IMRT. 

Extremely High Survival Rate
Five-year rates almost identical for low- and intermediate-risk patients. 

A Better Option for
Hypofractionated SBRT2

Shorter Treatment Schedules
Evidence suggests shortening treatment time to 5 fractions with SBRT does not increase gastrointestinal or acute toxicity, compared to conventional fractionation.

SBRT with Minimized Toxicity
CyberKnife SBRT reduced genitourinary side effects by 50% and also reduced gastrointestinal side effects, compared to SBRT with a conventional linac.

Enhanced Quality of Life
Reduced side effects and a shorter treatment schedule deliver meaningful quality-of-life benefits.

Confidence in Motion

How CyberKnife Redefines Prostate SBRT

The CyberKnife System is the only true robotic radiotherapy delivery system — and features the industry’s only real-time motion synchronization technology. Why does that matter?

Precision Matters

Delivering higher doses per fraction demands complete confidence in delivery precision and accuracy. CyberKnife’s continuous sub-millimeter precision allows zero-margin delivery to enable hypofractionated treatment while minimizing dose to healthy tissues.4

Learn more about the CyberKnife System.

Motion Management Matters

Normal bodily functions make intra-fractional prostate motion inevitable. The CyberKnife System uses the AI-powered Synchrony technology to continuously and automatically track and correct for target motion in real time, effectively targeting the cancer and minimizing dose to surrounding tissues.5

Learn more about Synchrony technology.

  1. Meier et al (2018) ‘Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: Survival and Toxicity Endpoints’. Int J Radiat Oncol Biol Phys. 102(2):206-303
  2. Tree et al (2022) ‘Intensity-Modulated Radiotherapy Versus Stereotactic Body Radiotherapy for Prostate Cancer (PACE-B): 2-year Toxicity Results From an Open-label, Randomised, Phase III Non-inferiority Trial’ Lancet Oncol https://doi.org/10.1016/S1470-2045(22)00517-4
  3. King CR, Freeman D, Kaplan I, et al. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol 2013; 109(2): 217-221.
  4. Fuller et al (2022) ‘High Dose “HDR-Like” Prostate SBRT: PSA 10-Year Results from a Mature, Multi-Institutional Clinical Trial’. Front Oncol. 29;12:935310
  5. Choi et al (2018) ‘Analysis of Motion-dependent Clinical Outcome of Tumor Tracking Stereotactic Bosy Radiotherapy for Prostate Cancer’ J Korean Med Sci. 2;33(14):e107

Request More Information

Connect with an Accuray expert. Get the answers you need.